先天性遺伝子・染色体異常:医療機器パイプライン分析

◆英語タイトル:Inborn Gene or Chromosome Alterations - Medical Devices Pipeline Assessment, 2019
◆商品コード:GDT20FB0194
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年12月
◆ページ数:498
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,000 ⇒換算¥424,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD8,000 ⇒換算¥848,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD12,000 ⇒換算¥1,272,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Inborn Gene or Chromosome Alterations – Medical Devices Pipeline Assessment, 2019
Summary

GlobalData’s Medical Devices sector report, “Inborn Gene or Chromosome Alterations – Medical Devices Pipeline Assessment, 2019″ provides an overview of Inborn Gene or Chromosome Alterations currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Inborn Gene or Chromosome Alterations pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Inborn Gene or Chromosome Alterations under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Inborn Gene or Chromosome Alterations and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to –
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Inborn Gene or Chromosome Alterations under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

【レポートの目次】

Table of Contents
1.1 List of Tables 14
1.2 List of Figures 26
2 Introduction 27
2.1 Inborn Gene or Chromosome Alterations Overview 27
3 Products under Development 28
3.1 Inborn Gene or Chromosome Alterations – Pipeline Products by Stage of Development 28
3.2 Inborn Gene or Chromosome Alterations – Pipeline Products by Territory 29
3.3 Inborn Gene or Chromosome Alterations – Pipeline Products by Regulatory Path 30
3.4 Inborn Gene or Chromosome Alterations – Pipeline Products by Estimated Approval Date 31
3.5 Inborn Gene or Chromosome Alterations – Ongoing Clinical Trials 32
4 Inborn Gene or Chromosome Alterations – Pipeline Products under Development by Companies 33
4.1 Inborn Gene or Chromosome Alterations Companies – Pipeline Products by Stage of Development 33
4.2 Inborn Gene or Chromosome Alterations – Pipeline Products by Stage of Development 39
5 Inborn Gene or Chromosome Alterations Companies and Product Overview 47
6 Inborn Gene or Chromosome Alterations- Recent Developments 282
7 Appendix 484

List of Tables
Table 1: Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development 28
Table 2: Inborn Gene or Chromosome Alterations - Pipeline Products by Territory 29
Table 3: Inborn Gene or Chromosome Alterations - Pipeline Products by Regulatory Path 30
Table 4: Inborn Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date 31
Table 5: Inborn Gene or Chromosome Alterations - Ongoing Clinical Trials 32
Table 6: Inborn Gene or Chromosome Alterations Companies - Pipeline Products by Stage of Development 33
Table 7: Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development 39
Table 8: AbaStar MDx Inc Pipeline Products & Ongoing Clinical Trials Overview 47
Table 9: Molecular Diagnostic Test - Bipolar Disorder - Product Status 47
Table 10: Molecular Diagnostic Test - Bipolar Disorder - Product Description 47
Table 11: Molecular Diagnostic Test - Depression - Product Status 48
Table 12: Molecular Diagnostic Test - Depression - Product Description 48
Table 13: Molecular Diagnostic Test - Parkinson's Disease - Product Status 48
Table 14: Molecular Diagnostic Test - Parkinson's Disease - Product Description 49
Table 15: Molecular Diagnostic Test - Schizophrenia - Product Status 49
Table 16: Molecular Diagnostic Test - Schizophrenia - Product Description 49
Table 17: Adipomics Inc Pipeline Products & Ongoing Clinical Trials Overview 50
Table 18: Diagnostic Test - Type 2 Diabetes - Product Status 50
Table 19: Diagnostic Test - Type 2 Diabetes - Product Description 50
Table 20: Advanced Genomic Technology, LLC Pipeline Products & Ongoing Clinical Trials Overview 51
Table 21: Blood MicroRNA-Based AD Diagnostic And Prognostic Kit - Product Status 51
Table 22: Blood MicroRNA-Based AD Diagnostic And Prognostic Kit - Product Description 51
Table 23: Agena Bioscience Inc Pipeline Products & Ongoing Clinical Trials Overview 52
Table 24: Sensigene Trisomy 21 Laboratory Developed Test - Product Status 52
Table 25: Sensigene Trisomy 21 Laboratory Developed Test - Product Description 52
Table 26: Alexion Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 53
Table 27: SmartPanel - Product Status 53
Table 28: SmartPanel - Product Description 53
Table 29: Amarantus Bioscience Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 54
Table 30: Diagnostic Test - IFN-Beta Resistance - Product Status 54
Table 31: Diagnostic Test - IFN-Beta Resistance - Product Description 54
Table 32: Amity University Pipeline Products & Ongoing Clinical Trials Overview 55
Table 33: Prenatal Screening Kit - Product Status 55
Table 34: Prenatal Screening Kit - Product Description 55
Table 35: Arrayit Corporation Pipeline Products & Ongoing Clinical Trials Overview 56
Table 36: PDx Pre-Symptomatic Test - Product Status 56
Table 37: PDx Pre-Symptomatic Test - Product Description 56
Table 38: Asuragen Inc Pipeline Products & Ongoing Clinical Trials Overview 57
Table 39: Diagnostic Test - Neurodegenerative Disorders - Product Status 57
Table 40: Diagnostic Test - Neurodegenerative Disorders - Product Description 57
Table 41: Signature CF Expand - Product Status 58
Table 42: Signature CF Expand - Product Description 58
Table 43: Augusta University Pipeline Products & Ongoing Clinical Trials Overview 59
Table 44: SUMO Gene Test - Type 1 Diabetes - Product Status 59
Table 45: SUMO Gene Test - Type 1 Diabetes - Product Description 59
Table 46: AutoGenomics Inc Pipeline Products & Ongoing Clinical Trials Overview 60
Table 47: DNA Guided Diagnostic Test - Cardiovascular Disease - Product Status 60
Table 48: DNA Guided Diagnostic Test - Cardiovascular Disease - Product Description 60
Table 49: DNA Guided Diagnostic Test - Diabetes - Product Status 61
Table 50: DNA Guided Diagnostic Test - Diabetes - Product Description 61
Table 51: DNA Guided Diagnostic Test - Obesity - Product Status 61
Table 52: DNA Guided Diagnostic Test - Obesity - Product Description 62
Table 53: INFINITI Factor II-V And MTHFR Assay - Product Status 62
Table 54: INFINITI Factor II-V And MTHFR Assay - Product Description 62
Table 55: INFINITI FMF Assay - Product Status 63
Table 56: INFINITI FMF Assay - Product Description 63
Table 57: INFINITI MTHFR Assay - Product Status 63
Table 58: INFINITI MTHFR Assay - Product Description 64

List of Figures
Figure 1: Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development 28
Figure 2: Inborn Gene or Chromosome Alterations - Pipeline Products by Territory 29
Figure 3: Inborn Gene or Chromosome Alterations - Pipeline Products by Regulatory Path 30
Figure 4: Inborn Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date 31
Figure 5: Inborn Gene or Chromosome Alterations - Ongoing Clinical Trials 32

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[先天性遺伝子・染色体異常:医療機器パイプライン分析]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆